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Sigma-2 receptor agonist derivatives of
1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-
tetrahydronaphthalen-1-yl)propyl]piperazine
(PB28) induce cell death via mitochondrial
superoxide production and caspase
activation in pancreatic cancer
Maria Laura Pati1†, John R. Hornick2†, Mauro Niso1, Francesco Berardi1, Dirk Spitzer2, Carmen Abate1*
and William Hawkins2
Abstract
Background: Despite considerable efforts by scientific research, pancreatic cancer is the fourth leading cause of
cancer related mortalities. Sigma-2 receptors, which are overexpressed in several tumors, represent promising
targets for triggering selective pancreatic cancer cells death.
Methods: We selected five differently structured high-affinity sigma-2 ligands (PB28, PB183, PB221, F281 and PB282)
to study how they affect the viability of diverse pancreatic cancer cells (human cell lines BxPC3, AsPC1, Mia PaCa-2,
and Panc1 and mouse Panc-02, KCKO and KP-02) and how this is reflected in vivo in a tumor model.
Results: Important cytotoxicity was shown by the compounds in the aggressive Panc02 cells, where cytotoxic
activity was caspase-3 independent for four of the five compounds. However, both cytotoxicity and caspase-3
activation involved generation of Reactive Oxygen Species (ROS), which could be partially reverted by the lipid
antioxidant α-tocopherol, but not by the hydrophilic N-acetylcysteine (NAC) indicating crucial differences in the
intracellular sites exposed to oxidative stress induced by sigma-2 receptor ligands. Importantly, all the compounds
strongly increased the production of mitochondrial superoxide radicals except for PB282. Despite a poor match
between in vitro and the in vivo efficacy, daily treatment of C57BL/6 mice bearing Panc02 tumors resulted in
promising effects with PB28 and PB282 which were similar compared to the current standard-of-care
chemotherapeutic gemcitabine without showing signs of systemic toxicities.
Conclusions: Overall, this study identified differential sensitivities of pancreatic cancer cells to structurally diverse
sigma-2 receptor ligands. Of note, we identified the mitochondrial superoxide pathway as a previously
unrecognized sigma-2 receptor-activated process, which encourages further studies on sigma-2 ligand-mediated
cancer cell death for the targeted treatment of pancreatic tumors.
Keywords: Sigma-2 receptor, Pancreatic cancer, Mitochondrial superoxide, Caspase-3 activity, Reactive oxygen
species
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Background
Despite considerable efforts in the field of oncology, cancer
remains one of the major public health problem world-
wide. Pancreatic cancer is the fourth leading cause of can-
cer related mortalities with an overall five-year survival rate
of only 7% [1]. Treatment with standard therapies offers
just some discreet prolongation of survival [2], while pre-
serving the best possible quality of life [3]. The prognosis
for pancreatic cancer remains poor due to a high rate of
local recurring event and metastatic disease [2]. Therefore,
development of alternative strategies for tumor treatment
is strongly needed. Novel compounds that exert anticancer
effect acting through diverse tumor-specific molecular tar-
gets are under study, and sigma receptors ligands are
among them. Sigma receptors subtypes, namely sigma-1
and sigma-2, are endocellular proteins highly expressed in
many tumors [4]. The sigma-1 receptor has been shown to
exert neuroprotective and neuroregulatiory functions is
linked to CNS pathologies such as schizophrenia, depres-
sion, Parkinson’s and Alzheimer’s diseases [5–10].
The sigma-2 subtype, has not yet been cloned, and
although its identification remains controversial [11–14],
increasing interest in this protein is due to its overex-
pression and activity in a number of human tumors.
Several sigma-2 ligands cause tumor selective cytotox-
icity and apoptosis, although the mechanism of cell
death induction is currently poorly understood but has
been shown to involve caspase-dependent and -inde-
pendent apoptosis, generation of reactive oxygen species
(ROS), and autophagy [15–20]. On the basis of previous
studies that showed certain sigma-2 agonists to be quite
effective in preclinical tumor models of pancreatic
cancer [21–24], we selected five sigma-2 ligands (Fig. 1,
PB28, PB183, PB221, F281 and PB282). While PB28 is a
well known sigma-2 agonist, the other compounds are
variants of PB28 with different hydrophobic or basic
moieties which were previously shown to bind sigma-2
receptors with high affinity (Table 1) [25–28]. In our
current study, we systematically tested these novel com-
pounds for relative effectiveness and relative toxicity in
pancreatic cancer in vitro and in vivo. While various
sigma-2 receptor ligands were capable of inducing apop-
tosis in tumor cells, the activation of caspase-3 and
upstream signaling events leading to cell death appeared
to depend on a particular combination of ligand and a
given cell type.
Herein we evaluated variants of PB28 in preclinical
models for efficacy in addition to define a mechanism of
action (mitochondrial superoxide production) that has
not been previously linked to a defined receptor medi-
ated process. Better understanding of the sensitivity of
cancers to some death pathways will help in tailoring the
sigma-2 receptor ligand treatment choice.
Methods
Cell culture
Human pancreas cancer cell lines BxPC3, AsPC1, Mia
PaCa-2, and Panc1 were obtained from American Type
Culture Collection (ATCC, Bethesda, MD; catalog num-
ber: CRL-1687, CRL-1682, CRL-1420, and CRL-1469
respectively). Murine pancreas adenocarcinoma Panc02
was a gift from Bryan Clary (Duke University). The mouse
KCKO cell line isolated from a spontaneously developing
pancreatic cancer overexpressing human MUC1 [29, 30]
was kindly provided by Dr. Pinku Mukherjee (University
of North Carolina, Charlotte, NC). The mouse KP-2 line
was derived from pancreatic cancer tumor tissue obtained
from p48-CRE/LSL-KrasG12D/p53flox/+ mice (backcrossed
Fig. 1 Sigma-2 receptor ligands PB28 and its analogues PB183, PB221, F281, PB282
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C57BL/6, n = 6). AsPC-1, BxPC-3 and Panc02 cells were
cultured in RPMI-1940 medium with 10% fetal bovine
serum (FBS). MIA PaCa-2 cells were cultured in Dulbec-
co’s Modified Eagle’s Medium (DMEM) with 10% FBS and
2.5% horse serum. PANC-1 cells were cultured in DMEM
with 10% FBS. KCKO cells were cultured in RPMI-1940
medium with 10% FBS, 1% sodium pyruvate, 1% HEPES
buffer, and 1% L-glutamine. KP-2 cells were cultured in
1:1 mixture of DMEM and Ham’s F-12 Nutrient Mixture
with 10% FBS. Penicillin (100 mg/mL) and streptomycin
(100 mg/mL) were added to all media; cells were main-
tained in a humidified incubator at 37 °C with 5% CO2.
Compounds
Sigma-2 receptor ligands PB28 [1-Cyclohexyl-4-[3-(5-
methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl] pipera-
zine], PB183 [1-Cyclohexyl-4-[3-(5-methoxynaphthalen-1-
yl)propyl]- piperazine], PB221 [4-Cyclohexyl-1-[3-(5-meth-
oxy-1,2,3,4-tetrahydronaphthalen- 1-yl-propyl)]piperidine],
F281 [1-Cyclohexyl-4-[3-(9H-carbazol-9-yl)propyl]pipera-
zine], and PB282 [cis-1-Cyclohexyl-4-[(2,6-difluorophenyl)-
cyclohexyl]piperazine] were synthesized in our laboratories
according to published methods [25–28]. Gemcitabine
and caspase-3 inhibitor Z-DEVD-FMK were pur-
chased from Tocris Bioscience, α-tocopherol and N-
Acetyl-L-cysteine from Sigma-Aldrich (St. Louis,
MO). Compounds were dissolved in DMSO with final
concentrations less than 0.3%.
Cell viability and ROS interference
Determination of cell growth was performed using the
MTT assay at 24 h [31, 32]. On day 1, pancreatic cancer
cell lines were plated at a density of 2 × 104 cells/well in
black clear-bottom 96-well plates for 24 h prior to treat-
ment in a volume of 100 μL. On day 2, the cells were
treated for 24 h with the various drugs concentration (1
μM-100 μM). Untreated cells served as a control. The
various drug-solvents (EtOH, DMSO) were added in
each control to evaluate a possible solvent cytotoxicity.
After the established incubation time with drugs (24 h),
MTT (0.5 mg/ml) was added to each well, and after 3–4
h incubation at 37 °C, the supernatant was removed.
The formazan crystals were solubilized using 100 μl of
DMSO/EtOH (1:1) and the absorbance values at 570
and 630 nm were determined on the multi-mode micro-
plate reader (BioTek instruments, Winooski, VT). Differ-
ent drug concentrations were assayed in triplicates.
The interference of ROS in cell viability was indirectly
determined by MTT assay reported above at 24 h. On day
1, Panc02 cells were plated at a density of 2 × 104 cells/
well in opaque 96-well, clear-bottom plates 24 h prior to
treatment. On day 2, cells were treated with the drugs (50
μM) in the presence or absence of α-tocopherol (100 μM)
or N-Acetyl-L-cysteine (100 μM). After incubation (24 h)
with drugs, MTTassay was performed as above.
Detection of caspase-3 activity in vitro
Caspase-3 activity was measured in Panc02 cell lines with
a Caspase-Glo® Assay Systems (Promega) according to
protocol in which the reagent contain luminogenic cas-
pase substrates that cleaved by activated caspase. Cells
were seeded at a density of 1 × 104 in black 96-well, clear
bottom plates for 24 h before treatment with 200 μM of
compounds in presence or absence of α-tocopherol (100
μM) or Z-DEVD-FMK (1μM) for 24 h after treatment.
The contents were then mixed using plate shaker for 30 s,
and incubated at room temperature for 90 min. Lumines-
cence signal was measured using multi-mode microplate
reader (BioTek). Assay was performed in triplicates, and
caspase activity was plotted compared cells treated with
DMSO as a control.
Detection of mitochondrial superoxide by flow cytometry
and ROS interference
MitoSOX™ Red reagent is a novel fluorogenic dye specif-
ically targeted to mitochondria in live cells. Oxidation of
MitoSOX™ Red reagent by superoxide produces red
fluorescence. Mitochondrial superoxide is generated as a
byproduct of oxidative phosphorylation. In an otherwise
tightly coupled electron transport chain, approximately
1–3% of mitochondrial oxygen consumed is incom-
pletely reduced; those “leaky” electrons can quickly
Table 1 Sigma-2 binding affinity and pancreatic cancer cell line viability, following sigma-2 receptor ligand treatment (24 h)
Cmpd Affinity (Ki, nM) Activity (EC50, μM)
σ2 Panc02 KP02 KCKO MIAPaCa-2 BxPC3 AsPC-1 Panc-1
PB28a 0.68 43 >100 87 51 >100 >100 >100
PB221a 18.8 37 >100 19 50 100 >100 >100
PB183b 9.24 83 97 51 49 100 >100 >100
F281c 12.6 37 49 62 29 42 98 >100
PB282d 14.1 >100 >100 90 51 >100 >100 >100
aSigma-2 binding data are from Berardi, et al. 2009 [26]; bSigma-2 binding data are from Berardi, et al. 2004 [25]; cSigma-2 binding data are from Ferorelli et al.,
2007 [27]; dSigma-2 binding data are from Abate, et al., 2011 [28]. Pancreas cancer cell lines were treated with escalating doses of the sigma-2 ligands PB28,
PB221, PB183, F281, PB282 or DMSO vehicle for 24 h and viability relative to vehicle determined by MTT Assay
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interact with molecular oxygen to form superoxide
anion, the predominant reactive oxygen species (ROS) in
mitochondria [33–36]. MitoSOX™ Red reagent is readily
oxidized by superoxide but not by other ROS- or react-
ive nitrogen species (RNS)–generating systems. Panc02,
AsPC-1, KP-2 or BxPC3 cells were seeded into 12-well
plates 24 h before treatment with sigma-2 ligands (50
μM) for 2 h at 37°C in presence or absence of α-
tocopherol (100 μM) followed by staining with Mito-
SOX™ Red (5 μM). Two hours after red dye addition, the
cells were washed twice with PBS and harvested with
trypsin/EDTA buffer. The cells were washed twice with
PBS before analysis with FACSCalibur (BD Bioscience,
San Jose, CA). The oxidation product of MitoSOX™ Red
by mitochondrial superoxide fluoresces with an emission
maximus of 580 nm and was detected in the FL3 chan-
nel. Experiment was performed in triplicates.
In vivo assessment of tumor growth and survival
Animal studies were performed according to the animal
studies protocol (20130073) approved by the Washington
University Institutional Animal Care Facility. In this pre-
clinical model, we utilized the Panc02 cell line [37], which
is weakly immunogenic in C57BL/6 mice and aggressive
with a subcutaneous inoculum of 1 × 105 cells being lethal
within 6–8 weeks. In vivo studies with mice were per-
formed to compare the effect of sigma-2 ligands with
gemcitabine. Mice treated with vehicle alone (a mixture of
5% DMSO, 5% EtOH, and 10% Cremophor in H2O)
served as the control cohort. Female C57BL/6 mice (10
weeks old, National Cancer Institute Laboratories) were
injected in the right flank with 200 μL of a single-cell sus-
pension of Panc02 cells in non-supplemented RPMI
medium (1 × 106 cells per mouse). Treatment began when
the mean tumor diameter was ~ 5 mm. Mice received
daily intraperitoneal (i.p.) injections of the sigma-2 ligands
PB28 (1.07 mg), PB221 (1.1 mg), PB183 (1.06 mg), F281
(1.05 mg), PB282 (1.09 mg), or gemcitabine (3 mg, once
weekly) in 100 μL vehicle or vehicle alone (control) for 2
weeks. Tumors were measured three times weekly in two
dimensions with a digital caliper, and tumor volumes were
calculated by the standard formula of Tumor Volume =
Length x Width2 × 0.5. All mice were euthanized when
tumors reached a diameter of 15 mm or had ulcerated.
Toxicity evaluation on mice not bearing tumor
Female C57BL/6 mice (8 weeks old, National Cancer In-
stitute Laboratories) received daily i.p. injections of the
sigma-2 ligands PB28 (1.07 mg), PB221 (1.1 mg), PB183
(1.06 mg), F281 (1.05 mg), PB282 (1.09 mg), in 100 μL
vehicle or vehicle alone (control) for 1 week. Mice from
each treatment cohort were assessed for pathologic
evaluation (Digestive Diseases Research Core Center at
our institution). Blood was collected for complete blood
count (CBC) and biochemical analysis (AST, ALT, BUN,
total protein, glucose and Cr). Organs were examined
grossly and histologically.
Statistical analysis
Statistical analyses and data plotting were performed
using GraphPad Prism software version 6.03 (San Diego,
CA). Results were expressed as mean ± standard error of
the mean of at least 3 biological replicates. EC50 values
were calculated by curve fitting normalized viability ver-
sus drug concentration. Differences in viability, caspase-
3 activity, and tumor volume were analyzed using two-
way ANOVA to identify differences and confirmed with
paired two tailed t-tests. Mann-Whitney test was used to
compare the difference in CBC and biochemistry ana-
lyses. Kaplan-Meier survival analyses were used to assess
differences between treatment groups and were com-
pared using a log-rank test. A p-value < 0.05 was consid-
ered significant for all analyses.
Results
Efficacy of PB28 variants against pancreatic cancer cell
lines in vitro
We assessed the cell killing activity of our drugs on a
panel of human (MIAPaCa-2, BxPC3, AsPC-1 and Panc-
1) and mouse (Panc02, KP-2 and KCKO) pancreatic can-
cer cell lines in vitro. The majority of the five compounds
tested (Fig. 1, PB28, PB221, PB183, F281 and PB282) re-
duced the viability in Panc02 (except for PB282), KCKO
and MIAPaCa-2 (Table 1). However, some cell lines
(AsPC1 and Panc-1) were resistant to all the compounds
we tested as demonstrated by EC50 > 100 μM. Two cell
lines (KP02 and BxPC3) were particularly sensitive to
F281 as demonstrated by intermediate anti-proliferative
activity (Table 1 EC50 ~ 45 μM). Notable differences were
recorded in the effect of the same compounds among
cells, such as F281 in Panc02, AsPC-1 and Panc-1 cells
(EC50 values = 37 μM, 98 μM or 100 μM, respectively).
Where active, compounds PB221 and F281 displayed the
most potent anti-proliferative activity with F281 displaying
a certain effect also in the BxPC3 cells. These results,
while suggesting differential sensitivities of cells to sigma-
2 receptor ligands, support their potential as therapeutics
for the treatment of pancreatic cancer.
Sigma-2 ligands induce caspase-3 activation
Sigma-2 ligands activated mechanisms are cell and ligand
specific and may cause both caspase-3 dependent and inde-
pendent apoptosis [15, 16, 22]. In order to test the effects of
our structurally diverse sigma-2 ligands regarding the
mechanism of cell death induction, activation of caspase-3
was assessed initially. To compare caspase-3 activity in-
duced by PB28, PB221, PB183, F281 and PB282, Panc02
mouse adenocarcinoma cells were treated with sigma-2
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ligands (200 μM) for 5 h and assayed for cleavage of the
proluminescent caspase-3 substrate and subsequent gener-
ation of a glow-type luminescent signal. PB221 and PB282
similarly induced a strong activation of caspase-3, increas-
ing caspase-3 activity by 15.7 and 11.8 fold (P < 0.001)
respectively compared to cells treated with DMSO vehicle
only. PB183 had little effect on caspase-3-like activity (P >
0.05) under these conditions, while PB28 and F281 did not
activate at all the caspase-3 at these concentrations, similar
to the DMSO control (Fig. 2a). To determine whether this
activity was caspase-3 specific, caspase-3 was also evaluated
in the presence of caspase-3 inhibitor Z-DEVD-FMK that
was used as a positive control for inhibition in the experi-
ment. The caspase-3 inhibitor Z-DEVD-FMK (1 μM) was
added one hour prior to PB221 and PB282 that are the two
sigma-2 ligands that showed the strongest caspase-3 activa-
tion. Five hours treatment with PB221 or PB282 caused
substantial caspase activation which was completely
blocked with Z-DEVD-FMK (Fig. 2b). Caspase-3 has been
extensively studied as a mechanism of sigma-2 receptor
ligand mediated apoptosis, and we wished to next examine
the role of ROS production by our structurally diverse
ligands. It turned out that following PB221 and PB282
treatment ROS production was completely blocked in the
presence of α-tocopherol (Fig. 2b).
Reactive oxygen species (ROS) involvement. Antioxidants
are protective of cellular toxicity
To assess the involvement of ROS production on cell
viability, we examined the effect antioxidants have on
the treatment of pancreatic cancer cells with our sigma-
2 ligands on cell death. The impact of antioxidants on
PANC02 cell viability was assessed 24 h after treatment
with PB28, PB221, PB183, F281 and PB282 (Fig. 2c).
Addition of 100 μM α-tocopherol one hour prior treat-
ment with sigma-2 ligands, rescued the viability of
Panc02 cells. ROS was only decreased following sigma-2
ligands treatment in the presence of α-tocopherol.
Fig. 2 Sigma-2 ligands induce caspase-3 activation and involve Reactive Oxygen Species (ROS) in Panc02 cell lines (a) Caspase-3 activation was measured
by Caspase-GloR Assay in Panc02 cells treated with 200 μM of different compounds for 5 h and expressed relative to vehicle. Cells treated with PB221
and PB282 had significant increase in caspase-3 p< 0.0001. b Panc02 cells were pre-treated with caspase-3 inhibitor Z-DEVD-FMK (1 μM) or DMSO vehicle
for one hour prior to exposure to sigma-2 ligands PB221, PB282 (200 μM) or DMSO vehicle for 5 h. The caspase-3 specific inhibitor Z-DEVD-FMK and
lipophilic antioxidant α-tocopherol abrogates caspase-3 dependent cleavage p < 0.0001. c Indirect measurement of ROS involvement following 24 h
treatment with 50 μM PB28, PB221, PB183, F281 or PB282 in the presence of 100 μM lipophilic antioxidant α-tocopherol or hydrophilic antioxidant
N-acetyl-L-cysteine (NAC), p= 0.002
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Interestingly, α-tocopherol protected against sigma-2
receptor ligands induced cell death, but N-acetyl-L-cyst-
eine (NAC) did not, and an even higher levels of cell death
was recorded when cells were co-treated with NAC and
PB183 or PB282. These results were confirmed also using
higher concentrations of NAC (10 mM).
Sigma-2 ligands generate superoxide radical in the
mitochondria of Panc02
MitoSOX™ Red reagent is a novel fluorogenic dye specific-
ally targeted to mitochondria in live cells. It is readily oxi-
dized by superoxide but not by other ROS- or reactive
nitrogen species (RNS)–generating systems (e.g. such as
peroxides, hydroxyl radical, singlet oxygen, nitric oxide and
peroxynitrite). Histograms of FACS analysis showed marked
increase of mean fluorescence intensity in Panc02 cells
treated with 50 μM of PB28, PB221, PB183, F281 or PB282
for 2 h (Fig. 3a). As a negative control DMSO treated cells
without MitoSOX™ were used. Quantitative measurements
of the mean fluorescence intensities from the samples dem-
onstrated between 20- to 23-fold increase in MitoSOX™
fluorescence intensity with sigma-2 ligands following treat-
ment except for cells treated with PB282 (6.7 fold compared
to cells treated with DMSO). In other pancreatic cancer cell
lines (AsPC1, BxPC3, KP-2) where these sigma-2 ligands
do not exert cytotoxic activity, much less superoxide radical
in the mitochondria was noted (Fig. 3b-d). Only F281 gen-
erated some mitochondrial superoxide in AsPC1 and
BxPC3 in line with its cytotoxic effect in these cells. With
the aim of obtaining a more complete picture, we evaluated
the mitochondrial superoxide production in the presence of
the antioxidant α-tocopherol. In all the pancreatic cancer
cell lines tested for this experiment, mitochondrial super-
oxide production was strongly decreased following sigma-2
ligands treatment in the presence of the lipid antioxidant α-
tocopherol (Fig. 3a-d).
In vivo tumor treatment: sigma-2 ligands confer a protective
effect against Panc02 tumor burden C57BL/6
Multiple structurally distinct compounds (Fig. 1) with high
affinity for sigma-2 receptors (Table 1) were tested for
cytotoxicity against multiple pancreatic cancer cell lines in
vitro (Table 1) and screened for efficacy in a mouse model
of pancreatic cancer with Panc02 cells. Here, we compared
the five selected sigma-2 ligands PB28, PB221, PB183,
F281 and PB282 against gemcitabine used as standard
control for pancreatic cancer. C57BL/6 female mice were
inoculated subcutaneously with 1 × 106 Panc02 cells and
10 days following tumor injection, when all mice had tu-
mors with a diameter of approximately 5 mm, mice were
randomized into treatments groups of (n = 7–10). Sigma-2
ligands PB28 (1.07 mg), PB221 (1.1 mg), PB183 (1.06 mg),
F281 (1.05 mg), PB282 (1.09 mg), or gemcitabine (3 mg,
once weekly) were given by i.p. injection daily for two
weeks (Fig. 4a-e). Following conclusion of treatment, tu-
mors were smaller for individual treatment groups PB28
Fig. 3 Sigma-2 Ligands generate Superoxide Radical in the Mitochondria. Mitochondrial Superoxide detection in (a) Panc02, (b) AsPC-1, (c) KP02,
(d) BxPC3, after 2 h treatment with 50 μM sigma-2 ligands alone or in combination with the lipid antioxidant α-tocopherol (1 mM). Values are the
means of n≥ 3 independent experiments in triplicates with SEM, p < 0.0001
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(mean = 369 mm3), (Fig. 4a), PB282 (mean = 483 mm3)
(Fig. 4e) and gemcitabine (mean = 395 mm3) compared to
vehicle (mean = 924 mm3) (p < 0.0001). PB28 and PB282
treated mice had similar tumor volumes that were statisti-
cally similar to gemcitabine. Even though treatment was
discontinued (on day 15), sigma-2 ligands also conferred a
survival advantage for mice in this experiment. The me-
dian survival for mice treated with DMSO was 23 days
compared to 27 and 29 days for mice treated with PB28
and PB282 respectively (Fig. 5a and e). All the other treat-
ment groups had a median survival of 25 to 27 days
(Fig. 5b-d). Mice appeared well throughout treatment
without signs of weight loss (Fig. 6a-e) and did not experi-
ence any treatment-related deaths.
Sigma-2 ligands have minimal toxicity in vivo
No toxicities were observed in the experiments above. How-
ever, the compounds localize to the tumors and therapeutic
Fig. 4 Sigma-2 ligands decrease Panc02 tumor burden in C57BL/6. One million Panc02 cells were inoculated subcutaneously into female,
10 week old C57BL/6 mice and when tumors had reached a mean diameter of 5 mm, daily sigma-2 ligand treatment or weekly gemcitabine began
by i.p. injection. PB28 (a) and PB282 (e) treatment decreased tumor volume similar to gemcitabine alone. PB221 (b) and F281 (d) treatment did not
confer a significantly different tumor volume than vehicle alone, while PB183 (c) treatment was not effective. Data represent Means ± SEM, n = 7-10
per group, p < 0.0001
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window might be different in non-tumor bearing animals.
In order to test this hypothesis, equimolar amounts of PB28
(1.07 mg), PB221 (1.1 mg), PB183 (1.06 mg), F281 (1.05
mg), PB282 (1.09 mg) were compared in C57BL/6 naïve fe-
male mice (n = 3) by daily treatment for one week. In order
to assess for more subtle toxicities, serum chemistries (AST,
ALT, BUN, total protein, glucose, and Cr) and complete
blood counts were analyzed and there were no significant
differences (Table 2). Gross pathology and histology reports
of brain, kidney, liver, and pancreas were not appreciably
different from untreated control animals (data not shown).
Discussion
Currently available chemotherapeutics have poor efficacy
in pancreatic cancer patients. Chemotherapeutic drugs
enter normal and cancer tissues with similar kinetics,
resulting in toxic effects on normal tissues often leading
to changes in the therapeutic plan such as dose reduc-
tions that leads to less effective drug combinations and
discontinuation of therapy. Without specific targeting of
these treatments, off-site toxicities can occur and the
therapeutic window can be reduced. Sigma-2 receptors
ligands appear to be selective to cancers: sigma-2
Fig. 5 Survival Curve. Survival of mice treated with (a) PB28; (b) PB221; (c) PB183; (d) F281; (e) PB282 compared to the mice treated with vehicle (p > 0.05
for PB221 and p < 0.05 for all the other compounds) or Gemzar. Survival endpoints were defined as tumor diameter > 15 mm or tumor ulceration
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receptors are highly expressed in tumor cells and allow
selective targeting of cancers [38]. Sigma-2 ligands have
been demonstrated to image not only pancreatic tumors
in animal models [21] but, more importantly, in clinical
imaging studies [39].
PB28 and PB282 compounds previously showed en-
couraging results in vitro and in vivo on the viability of
BxPC3 pancreatic cancer cells [24]. Therefore, herein,
we selected five different sigma-2 ligands, that were
tested on a wide panel of human and mouse pancreatic
adenocarcinoma cell lines in vitro.
Most of the compounds displayed high sigma-2 affinity
and exerted appreciable cytotoxic activity in some pan-
creatic cancer cell lines. We showed that, in particular,
F281 had a greater capacity to decrease viability in the
pancreas cancer cell lines tested, except for Panc1. The
mechanism by which sigma-2 ligands, at high doses,
induce cell death is not completely understood. We do
know that sigma-2 ligands induce apoptosis by caspase-
3 dependent and independent mechanisms [16, 22, 40].
The generation of reactive oxygen species (ROS) has
been well demonstrated to be both a by-product and a
promoter of apoptosis and necrosis. of The apoptotic
signals is intracellularly transmitted through production
of ceramide or through direct effect on the mitochondria
[41]. Diverse mechanisms of apoptosis by ROS are
known and may be cell-type dependent, while antioxi-
dants or intracellular enzymes such as superoxide
Fig. 6 C57BL/6 mice tolerated the drugs well without signs of weight loss. a PB28; (b) PB221; (c) PB183; (d) F281; (e) PB282. Data represent
Means ± SEM, n = 7–10 per group p < 0.0001
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dismutase, catalase, and glutathione peroxidase have
been shown to protect against ROS. We observed that
the five sigma-2 agonists induced ROS in Panc02 cells
and that apoptosis could be partially ameliorated by
treatment with the antioxidant α-tocopherol. On the
other hand, in this study, the small diffusible hydrophilic
antioxidant NAC, a precursor of glutathione, did not
protect against cell death by sigma-2 ligands, resulting in
an even higher toxicity in co-administration assays with
PB183 and PB282. Since at low concentrations (100
μM), there are chances that NAC behaves as an oxidant
(rather than acting as an antioxidant or a radical scaven-
ger), higher concentrations of NAC (10 mM) were also
used but results did not change. NAC is a general redu-
cing agent whereas α-tocopherol protects against oxida-
tive stress is by preventing membrane lipid peroxidation,
so that we believe that our results indicate crucial differ-
ences in the intracellular sites exposed to oxidative stress
by sigma-2 receptor ligands. By contrast, PB282 did not
show cytotoxic activity in Panc02 cell lines. However,
only PB282 and PB221, at the concentration and time
point used, were able to generate a strong caspase-3 ac-
tivation, which was completely blocked by α-tocopherol
and by caspase-3 inhibitor Z-DEVD-FMK. Since PB28,
PB183, PB221 and F281 showed cytotoxicity in Panc02
cells, these results suggest that their cytotoxic activity is
caspase-3 independent, except for PB221 that strongly
activated caspase-3, but both cytotoxity and caspase-3
activation involved ROS generation. In addition, all the
compounds strongly increased superoxide mitochondrial
radical production except for PB282. This result suggests
that superoxide mitochondrial radical production is one
of the factors responsible for the cytotoxic effect of these
ligands. In line with this result, in other pancreatic can-
cer cell lines where these sigma-2 ligands do not induce
appreciable cytotoxicity (AsPC1, BxPC3, KP-2), much
less superoxide radical formation in the mitochondria
was detected. Only F281 generated some mitochondrial
superoxide in AsPC1 and BxPC3, where a moderate
cytotoxicity was noticed, in line with the hypothesis that
mitochondrial superoxide pathway is at least partially
responsible for the cytotoxic activity caused by our com-
pounds in pancreatic cancer cells. These data indicate
that structurally diverse sigma-2 ligands can activate
different pathways in a panel of diverse cancer cell lines,
and for the first time mitochondrial superoxide pathway
was demonstrated for sigma-2 ligands. To verify that
these in vitro results could potentially translate into an
anti-tumorigenic effects in vivo, we utilized the aggres-
sive cell line Panc02 in a syngeneic model of pancreatic
cancer using C57BL/6 mice. We have shown that our
treatment schedule resulted in minimal off-target toxic-
ities in vivo (measured by serum studies and body weight)
and was well tolerated. Although PB282 did not show
cytotoxicity in Panc02 cells in vitro, daily treatment with
PB28 and PB282 produced an effect statistically similar to
gemcitabine alone, while other compounds such as PB221
and F281, that showed good EC50 values in this cell line in
vitro, did not perform as well in vivo. This could be due to
metabolic effects observed in in vivo experiment. In
Table 2 Sigma-2 ligands do not induce changes in blood cytology (CBC) following treatment of not tumor-bearing C57BL/6 mice
Control PB28 PB221 PB183 PB282 p-value
A.
WBC (103/μL) 10.58 ± 0.2 11.11 ± 1.97 8.12 ± 0.14 6.42 ± 1.22 5.78 ± 0.78 0.9
RBC (106/μL) 7.14 ± 0.1 10.24 ± 0.3 9.59 ± 0.71 9.24 ± 0.9 9.91 ± 0.31 0.9
HGB (g/dL) 10.7 ± 0.7 15.65 ± 0.55 14.7 ± 0.8 14.85 ± 1.35 15 ± 0.4 0.4
HCT (%) 36.6 ± 0.08 53.4 ± 1.5 50.35 ± 3.75 48.8 ± 3.3 51.1 ± 1.9 0.9
MCV (fL) 51.2 ± 0.32 52.15 ± 0.05 52.5 ± 0.02 52.9 ± 1.6 51.55 ± 0.35 0.6
MCH (pg) 15 ± 0.54 15.3 ± 0.1 15.35 ± 0.35 16.1 ± 0.1 15.15 ± 0.05 0.9
MCHC (%) 29.2 ± 1.21 29.3 ± 0.2 29.25 ± 0.55 30.4 ± 0.7 29.4 ± 0.3 0.9
Platelets (103/μL) 486 ± 67 643.5 ± 95.5 563 ± 17 727.5 ± 65.5 649.5 ± 167.5 0.5
B.
BUN (mg/dL) 27 ± 0.4 32 ± 1 30.5 ± 3.5 21 ± 2 24.5 ± 0.5 0.9
Creatinine (mg/dL) 0.34 ± 0.02 0.37 ± 0.04 0.35 ± 0.03 0.37 ± 0.04 0.35 ± 0.03 0.9
ALT (μ/L) 260 ± 21 249 ± 9 219 ± 5 203 ± 34 221 ± 63 0.8
AST (μ/L) 5.6 ± 0.05 5.85 ± 0.35 5.35 ± 0.05 5.4 ± 0.5 5.5 ± 0.07 0.7
Total Protein (g/dL) 168 ± 42 194 ± 72 67.5 ± 1.5 197 ± 103 164 ± 52 0.9
Glucose (mg/dL) 62 ± 12.5 92.5 ± 22.5 64.5 ± 7.5 125 ± 55 60 ± 10 0.4
(A) Blood cytology analysis of C57BL/6 mice (n = 3 mice/group) treated with S2L and vehicle (control) for 5 days. The differences in complete blood count
laboratory values between the two groups are not statistically significant. (B) Biochemical analysis of C57BL/6 mice (n = 3 mice/group) treated with sigma-2 ligands
and vehicle (control) for 5 days. The differences in serum chemistries between the groups are not statistically significant
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particular, PB282 could produce active metabolites, in
contrast to PB221, PB183 and F281 that are less effective
in vivo despite their higher toxicity in the same tumor in
vitro. We would also consider that survival would have
likely been further increased if the treatment duration
would have been extended since tumor volume was stabi-
lized during the limited treatment period of only two
weeks, without anticipating additional off-site toxicities.
Along these lines, necropsy and laboratory evaluations
demonstrated that PB28, PB221, PB183, F281 and PB282
had no major off-target effects even in naïve mice during
continuous treatment as they well tolerated the drugs
without signs of weight loss and no casualties as a result
of drug treatments.
Conclusions
Overall, this study confirmed sigma-2 receptors as a
promising target for the targeted treatment of pancreatic
tumors, while mitochondrial superoxide production was
identified as a novel mechanism of sigma-2 receptor-
mediated cell death.
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